LONDON – Novabiotics Ltd. is poised to close a $15 million funding round that will enable it to move its lead antimicrobial peptide product, Novexatin, into a Phase IIb trial in nail fungal infection onchomycosis and to advance its second program, Lynovex, into a Phase IIa trial in cystic fibrosis.